1. CP-1 Lenalidomide Nonclinical Overview Dr. David Stirling Chief Scientific Officer Celgene Corporation

2. CP-2 Lenalidomide Nonclinical Pharmacokinetic Studies  Rapidly absorbed  Extensive distribution into tissues  Low protein binding  Does not inhibit or induce major cytochrome P450 isozymes  Partial metabolism related to hydrolysis observed in vivo  Rapidly excreted via the urine mainly as unchanged drug

3. CP-3 Lenalidomide vs Thalidomide  Lenalidomide and thalidomide are pharmacologically different drugs based on – Chemistry/metabolism Structurally linked No common breakdown products – Cellular biology Significant potency differences – Molecular biology Del 5q sensitivity – Clinical profile Different safety profiles – Non-clinical reproductive/development toxicology Lenalidomide is not selectively toxic to development Lenalidomide did not produce limb malformations

4. CP-4 Reproductive and Developmental Toxicity Additional Studies in Rabbits  Pulse dosing study completed – High dose on GDs 8 through 10 – No malformations  Additional Seg II studies in progress – Dose-ranging study with TK completed – Developmental toxicity study completed – Analysis and report preparation underway

5. CP-5 Lenalidomide: Cellular Mechanism  Anti-proliferative (proapoptotic, cell cycle arrest)  Proerythropoietic (stimulate HbF synthesis)  Cytokine regulation (TNFα, IL-10, IL-2, IFN-γ)  Immune stimulation (T cells, NK cells)  Anti-angiogenic  Expand progenitor cell populations